Magdy Selim

Division Chief, Stroke & Cerebrovascular Diseases · Beth Israel Deaconess Medical Center

Credentials: · · · · ·

History

Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation (MINUTE) Trial
National Institute of Neurological Disorders and Stroke · UH3
PI · $3.7M · Weill Medical Coll of Cornell Univ
2025–2030
StATins Use in intRacerebral Hemorrhage patieNts (SATURN)
National Institute of Neurological Disorders and Stroke · U01
Contact PI · $15.7M · Beth Israel Deaconess Medical Center
2019–2028
StAtins Use in intRacereberal Hemorrhage patieNts MRI (SATURN MRI) Ancillary Study
National Institute of Neurological Disorders and Stroke · U01
Contact PI · $2.1M · Beth Israel Deaconess Medical Center
2021–2027
Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation (MINUTE) Trial
National Institute of Neurological Disorders and Stroke · UG3
PI · $2.3M · Icahn School of Medicine at Mount Sinai
2025–2026

Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation
Principal investigator · Recruiting
Weill Medical College of Cornell University
2026–2030
High-Dose Deferoxamine in Intracerebral Hemorrhage
Principal investigator · Terminated · Phase 2
Beth Israel Deaconess Medical Center
2013–2018
Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage
Principal investigator · Completed · Phase 1
Beth Israel Deaconess Medical Center
2008–2010
Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial
Study chair · Completed · Phase 2
Beth Israel Deaconess Medical Center
2014–2018